Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.

Marco Antonio Mascarella Tolani F Olonisakin Purva H Rumde Varun Vendra Melonie A Nance Seungwon Kim Mark W Kubik Shaum S Sridharan Matthew J Ferris Moon J Fenton Daniel R Clayburgh James P Ohr Sonali C Joyce Malabika Sen James G Herman Jennifer R Grandis Dan P Zandberg Umamaheswar Duvvuri

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Brief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.

Keyphrases

locally advanced
rectal cancer
lymph node
end stage renal disease
ejection fraction
newly diagnosed
stem cells
transcription factor
prognostic factors
squamous cell carcinoma
radiation therapy
patient reported outcomes
mesenchymal stem cells
bone marrow